Cyramza (ramucirumab) — Medical Necessity Criteria
Clinical criteria governing medical-benefit coverage and prior authorization for Cyramza (ramucirumab) for multiple oncology indications for Anthem members in North Carolina.
Update hepatocellular carcinoma criteria; update esophageal, gastric, gastroesophageal adenocarcinoma criteria; update non-small cell lung cancer criteria; add thymic carcinoma criteria; coding reviewed with additions and removals.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.